CYP2C19 and breast cancer: Therefore, it is of interest to assess the correlation ofCYP1A1, CYP1B1, CYP2C genotypes with treatment efficacy and clinical outcomes in breast cancer patients administered with doxorubicinand paclitaxel based chemotherapy.